Suppr超能文献

吸烟、饮酒及其他导致有症状新冠病毒病与无症状严重急性呼吸综合征冠状病毒2感染的风险因素:一项来自印度拉贾斯坦邦西部的病例对照研究

Tobacco, alcohol use and other risk factors for developing symptomatic COVID-19 vs asymptomatic SARS-CoV-2 infection: a case-control study from western Rajasthan, India.

作者信息

Saurabh Suman, Verma Mahendra Kumar, Gautam Vaishali, Kumar Nitesh, Jain Vidhi, Goel Akhil Dhanesh, Gupta Manoj Kumar, Sharma Prem Prakash, Bhardwaj Pankaj, Singh Kuldeep, Nag Vijaya Lakshmi, Garg Mahendra Kumar, Misra Sanjeev

机构信息

Department of Community Medicine and Family Medicine, All India Institute of Medical Sciences, Jodhpur, Rajasthan 342005, India.

Department of Microbiology, All India Institute of Medical Sciences, Jodhpur, Rajasthan 342005, India.

出版信息

Trans R Soc Trop Med Hyg. 2021 Jul 1;115(7):820-831. doi: 10.1093/trstmh/traa172.

Abstract

BACKGROUND

Understanding risk factors of symptomatic coronavirus disease 2019 (COVID-19) vis-à-vis asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, severe disease and death is important.

METHODS

An unmatched case-control study was conducted through telephonic interviews among individuals who tested positive for SARS-CoV-2 in Jodhpur, India from 23 March to 20 July 2020. Contact history, comorbidities and tobacco and alcohol use were elicited using standard tools.

RESULTS

Among 911 SARS-CoV-2-infected individuals, 47.5% were symptomatic, 14.1% had severe COVID-19 and 41 (4.5%) died. Older age, working outside the home, cardiac and respiratory comorbidity and alcohol use were found to increase the risk of symptomatic disease as compared with asymptomatic infection. Current tobacco smoking (odds ratio [OR] 0.46 [95% confidence interval {CI} 0.26 to 0.78]) but not smokeless tobacco use (OR 0.81 [95% CI 0.55 to 1.19]) appeared to reduce the risk of symptomatic disease. Age ≥60 y and renal comorbidity were significantly associated with severe COVID-19. Age ≥60 y and respiratory and cardiac comorbidity were found to predispose to mortality.

CONCLUSIONS

The apparent reduced risk of symptomatic COVID-19 among tobacco smokers could be due to residual confounding owing to unknown factors, while acknowledging the limitation of recall bias. Cross-protection afforded by frequent upper respiratory tract infection among tobacco smokers could explain why a similar association was not found for smokeless tobacco use, thereby being more plausible than the 'nicotinic hypothesis'. Those with comorbidities and age ≥60 y should be prioritized for hospital admission.

摘要

背景

了解2019冠状病毒病(COVID-19)症状性感染相对于无症状严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染、重症疾病和死亡的风险因素很重要。

方法

通过电话访谈对2020年3月23日至7月20日在印度焦特布尔SARS-CoV-2检测呈阳性的个体进行了一项非匹配病例对照研究。使用标准工具获取接触史、合并症以及烟草和酒精使用情况。

结果

在911名感染SARS-CoV-2的个体中,47.5%有症状,14.1%患有重症COVID-19,41人(4.5%)死亡。与无症状感染相比,年龄较大、外出工作、心脏和呼吸系统合并症以及饮酒会增加出现症状性疾病的风险。当前吸烟(比值比[OR]0.46[95%置信区间{CI}0.26至0.78])而非使用无烟烟草(OR 0.81[95%CI 0.55至1.19])似乎会降低出现症状性疾病的风险。年龄≥60岁和肾脏合并症与重症COVID-19显著相关。年龄≥60岁以及呼吸系统和心脏合并症易导致死亡。

结论

吸烟者中COVID-19症状性感染风险明显降低可能是由于未知因素导致的残余混杂,同时承认存在回忆偏倚的局限性。吸烟者频繁的上呼吸道感染所提供的交叉保护可以解释为什么无烟烟草使用未发现类似关联,因此比“尼古丁假说”更具合理性。合并症患者和年龄≥60岁的患者应优先住院治疗。

相似文献

2
SARS-CoV-2 infection and mortality during the first epidemic wave in Madurai, south India: a prospective, active surveillance study.
Lancet Infect Dis. 2021 Dec;21(12):1665-1676. doi: 10.1016/S1473-3099(21)00393-5. Epub 2021 Aug 13.
4
Workplace interventions to reduce the risk of SARS-CoV-2 infection outside of healthcare settings.
Cochrane Database Syst Rev. 2022 May 6;5(5):CD015112. doi: 10.1002/14651858.CD015112.pub2.
5
Workplace interventions to reduce the risk of SARS-CoV-2 infection outside of healthcare settings.
Cochrane Database Syst Rev. 2024 Apr 10;4(4):CD015112. doi: 10.1002/14651858.CD015112.pub3.
7
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
Cochrane Database Syst Rev. 2022 Sep 20;9(9):CD015395. doi: 10.1002/14651858.CD015395.pub2.
8
Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.
Cochrane Database Syst Rev. 2021 Feb 12;2(2):CD013587. doi: 10.1002/14651858.CD013587.pub2.
9
Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the Diamond Princess cruise ship: a retrospective analysis.
Lancet Infect Dis. 2020 Sep;20(9):1043-1050. doi: 10.1016/S1473-3099(20)30482-5. Epub 2020 Jun 12.

引用本文的文献

2
Prevalence and association between alcohol, tobacco, and COVID-19: a study from a tribal predominant district in eastern India.
Front Public Health. 2024 Aug 16;12:1415178. doi: 10.3389/fpubh.2024.1415178. eCollection 2024.
3
Evaluating the protective effectiveness and risk factors of ursodeoxycholic acid on COVID-19 among outpatients.
Front Pharmacol. 2024 Jul 31;15:1381830. doi: 10.3389/fphar.2024.1381830. eCollection 2024.
4
Association of Alcohol Use with COVID-19 Infection and Hospitalization Among People Living with HIV in the United States, 2020.
AIDS Behav. 2024 May;28(5):1795-1807. doi: 10.1007/s10461-024-04301-6. Epub 2024 Feb 29.
5
Spatio-temporal epidemiology and associated indicators of COVID-19 (wave-I and II) in India.
Sci Rep. 2024 Jan 2;14(1):220. doi: 10.1038/s41598-023-50363-2.
6
Unintended Consequences of COVID-19 Non-Pharmaceutical Interventions (NPIs) for Population Health and Health Inequalities.
Int J Environ Res Public Health. 2023 Mar 23;20(7):5223. doi: 10.3390/ijerph20075223.
7
The role of smoking in COVID-19 progression: a comprehensive meta-analysis.
Eur Respir Rev. 2023 Mar 8;32(167). doi: 10.1183/16000617.0191-2022. Print 2023 Mar 31.
8
Asymptomatic versus symptomatic SARS-CoV-2 infection: a cross-sectional seroprevalence study.
Trop Med Health. 2022 Dec 27;50(1):98. doi: 10.1186/s41182-022-00490-9.
9
Lower SARS-CoV-2 household transmission in children and adolescents compared to adults.
Sci Rep. 2022 Dec 27;12(1):22453. doi: 10.1038/s41598-022-24643-2.

本文引用的文献

1
Serologic Cross-Reactivity of SARS-CoV-2 with Endemic and Seasonal Betacoronaviruses.
J Clin Immunol. 2021 Jul;41(5):906-913. doi: 10.1007/s10875-021-00997-6. Epub 2021 Mar 16.
2
Cross-reactivity towards SARS-CoV-2: the potential role of low-pathogenic human coronaviruses.
Lancet Microbe. 2020 Aug;1(4):e151. doi: 10.1016/S2666-5247(20)30098-7. Epub 2020 Aug 6.
3
Nicotine treatment and smoking cessation in the era of COVID-19 pandemic: an interesting alliance.
ERJ Open Res. 2020 Aug 11;6(3). doi: 10.1183/23120541.00306-2020. eCollection 2020 Jul.
5
A nicotinic hypothesis for Covid-19 with preventive and therapeutic implications.
C R Biol. 2020 Jun 5;343(1):33-39. doi: 10.5802/crbiol.8.
6
The role of host genetics in the immune response to SARS-CoV-2 and COVID-19 susceptibility and severity.
Immunol Rev. 2020 Jul;296(1):205-219. doi: 10.1111/imr.12897. Epub 2020 Jul 13.
8
Current smoking, former smoking, and adverse outcome among hospitalized COVID-19 patients: a systematic review and meta-analysis.
Ther Adv Chronic Dis. 2020 Jun 25;11:2040622320935765. doi: 10.1177/2040622320935765. eCollection 2020.
9
Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals.
Cell. 2020 Jun 25;181(7):1489-1501.e15. doi: 10.1016/j.cell.2020.05.015. Epub 2020 May 20.
10
Silent hypoxia: A harbinger of clinical deterioration in patients with COVID-19.
Am J Emerg Med. 2020 Oct;38(10):2243.e5-2243.e6. doi: 10.1016/j.ajem.2020.05.044. Epub 2020 May 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验